Opinion|Videos|July 29, 2024
Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
A panel of experts discuss switching between different antihistimines and other medications when treating CSU patients.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- A significant number of patients with CSU do not respond adequately to antihistamines. What is your approach to switching between (or adding on) antihistamines and when do you switch to another class of medications?
- How does antihistamine switching and treatment selection correlate with timing of disease episodes?
- If patients aren’t responding well to antihistamines, which therapies do you use next? When do you consider using biologics? What considerations do you take into account and what ultimately is driving that decision?
Advertisement
Related to this article
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
5 Things to Know if Retatrutide Is Classified as a Biologic
4
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
5